Clinical characteristics and treatment of outpatients with chronic heart failure in the Moscow Region

Cover Page


Cite item

Full Text

Abstract

Aim: To perform clinical characterization of patients with chronic heart failure (CHF) in the Moscow Region and to assess if their current treatments meet the current clinical guidelines.

Materials and methods: Based on the information submitted from 11  outpatient clinics in the Moscow Region in December 2019, we analyzed retrospective data on 286  patients with CHF, including their concomitant diseases, types of assessments and their results, as well as current treatments.

Results: The most common concomitant disease was arterial hypertension (95.1%  of the patients). 53.8% of the patients had previous myocardial infarction, 37.8%, diabetes mellitus, and 34.6%, atrial fibrillation. Chronic kidney disease was present in 18.5% of the patients, valvular heart disease in 11.9%, and past stroke in 10.5%. Of non-cardiovascular diseases, the most common were gastrointestinal disorders (25.2%), chronic obstructive pulmonary disease or asthma (9.8%), and anemia (5.2%). Only 8% of the patients had one concomitant disease, whereas 72%  had 2  to 3  diseases, and 20%  had at least 4  concomitant diseases. Mean number of comorbidities per patient was 2.7. Echocardiography had been performed in 82.9% of the cases. Mean left ventricular ejection fraction was 51.0±10.11%; in 11.5% of the patients it was≤40%. Glomerular filtration rate (GFR) was calculated in 58.7%  of the patients. 35.9%  of the patients had a GFR of less than 60 mL/min/1.73 m2 , in  3.6% it was≤30  mL/min/1.73  m2 . 83.2% of the patients were treated with renin angiotensin aldosterone system blockers (angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, sacubitril/valsartan), 79.0% with beta-blockers, 53.1% with mineralocorticoid receptor antagonists. Glycosides had been administered to 6.9% of the patients, and diuretics, to 51.1%. In most cases, the doses administered were below those recommended by the international clinical guidelines.

Conclusion: We have confirmed the need to increase the adherence of doctors to the clinical guidelines on assessment and management of CHF patients.

About the authors

T. K. Chernyavskaya

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: corona1974@mail.ru

Tat'yana K. Chernyavskaya – MD, PhD, Associate Professor, Deputy Director on Organizational and Methodological Work

61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Россия

M. G. Glezer

I.M. Sechenov First Moscow State Medical University

Email: 287ast@mail.ru
ORCID iD: 0000-0002-0995-1924

Maria G. Glezer – MD, PhD, Professor, Chair of Cardiology, Functional and Ultrasonic Diagnostics, Institute of Clinical Medicine named after N.V. Sklifosovskiy

8/2 Trubetskaya ul., Moscow, 119991, Russian Federation 

Россия

References

  1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. doi: 10.1093/eurheartj/ehw128.
  2. Мареев ВЮ, Фомин ИВ, Агеев ФТ, Беграмбекова ЮЛ, Васюк ЮА, Гарганеева АА, Гендлин ГЕ, Глезер МГ, Готье СВ, Довженко ТВ, Кобалава ЖД, Козиолова НА, Коротеев АВ, Мареев ЮВ, Овчинников АГ, Перепеч НБ, Тарловская ЕИ, Чесникова АИ, Шевченко АО, Арутюнов ГП, Беленков ЮН, Галявич АС, Гиляревский СР, Драпкина ОМ, Дупляков ДВ, Лопатин ЮМ, Ситникова МЮ, Скибицкий ВВ, Шляхто ЕВ. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8–158. doi: 10.18087/cardio.2475.
  3. Орлова ЯА, Ткачёва ОН, Арутюнов ГП, Котовская ЮВ, Васюк ЮА, Лопатин ЮМ, Мареев ВЮ, Мареев ЮВ, Стражеско ИД, Скворцов АА, Рунихина НК, Фролова ЕВ. Особенности диагностики и лечения хронической сердечной недостаточности у пациентов пожилого и старческого возраста. Мнение экспертов Общества специалистов по сердечной недостаточности, Российской ассоциации геронтологов и гериатров и Евразийской ассоциации терапевтов. Кардиология. 2018;58(12S):42–72. doi: 10.18087/cardio.2560.
  4. Беленков ЮН. Влияние специализированных форм активного амбулаторного ведения на функциональный статус, качество жизни и показатели гемодинамики больных с выраженной сердечной недостаточностью. Результаты Российской программы «ШАНС». Сердечная недостаточность. 2007;8(3):112–116.
  5. Task force of the Hellenic Heart Failure Clinics Network. How to develop a national heart failure clinics network: a consensus document of the Hellenic Heart Failure Association. ESC Heart Fail. 2020;7(1):15–25. doi: 10.1002/ ehf2.12558.
  6. Gandhi S, Mosleh W, Sharma UC, Demers C, Farkouh ME, Schwalm JD. Multidisciplinary Heart Failure Clinics Are Associated With Lower Heart Failure Hospitalization and Mortality: Systematic Review and Meta-analysis. Can J Cardiol. 2017;33(10):1237–1244. doi: 10.1016/j.cjca.2017.05.011.
  7. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst WH, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24(5):464–474. doi: 10.1016/ s0195-668x(02)00700-5.
  8. Виноградова НГ, Жиркова ММ, Фомин ИВ, Поляков ДС. Эффективность лечения хронической сердечной недостаточности на амбулаторном этапе в условиях городского центра ХСН. Сердечная недостаточность. 2017;18(4):270–278. doi: 10.18087/ RHFJ.2017.4.2355.
  9. van Deursen VM, Urso R, Laroche C, Damman K, Dahlström U, Tavazzi L, Maggioni AP, Voors AA. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014;16(1):103–111. doi: 10.1002/ejhf.30.
  10. Kristensen SL, Martinez F, Jhund PS, Arango JL, Bĕlohlávek J, Boytsov S, Cabrera W, Gomez E, Hagège AA, Huang J, Kiatchoosakun S, Kim KS, Mendoza I, Senni M, Squire IB, Vinereanu D, Wong RC, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJ. Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J. 2016;37(41):3167–3174. doi: 10.1093/eurheartj/ehw226.
  11. Управление Федеральной службы государственной статистики по г. Москве и Московской области. Московская область в цифрах: Статистический сборник [Интернет]. М.; 2020. 390 с. Доступно на: https:// mosstat.gks.ru/storage/mediabank/MTaTDg7F/%D0%9C%D0%9E%20%D0%B2%20 %D1%86%D0%B8%D1%84%D1%80%D0%B 0%D1%85%202019.pdf.
  12. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L; Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808–817. doi: 10.1093/eurjhf/hft050.
  13. Фомин И.В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. В: Агеев ФТ, ред. Хроническая сердечная недостаточность. М.: ГЭОТАР-Медиа; 2010. с. 7–77.
  14. Фомин ИВ. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;(8): 7–13. doi: 10.15829/1560-4071-2016-8-7-13.
  15. Краием Н, Поляков ДС, Фомин ИВ, Виноградова НГ, Валикулова ФЮ, Вайсберг АР, Бадин ЮВ, Щербинина ЕВ. Динамика распространенности хронической сердечной недостаточности и сахарного диабета в Нижегородской области с 2000 по 2017 год. Кардиология. 2018;58(2S):25–32. doi: 10.18087/cardio.2439.
  16. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir O, Logeart D, Dahlström U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A; Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18(6):613–625. doi: 10.1002/ejhf.566.
  17. Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L; Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15(10):1173–1184. doi: 10.1093/eurjhf/hft134.
  18. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors A, Nielsen OW, Zannad F, Tavazzi L; Heart Failure Association of ESC (HFA). EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2010;12(10):1076–1084. doi: 10.1093/eurjhf/ hfq154.
  19. Düngen HD, Apostolovic S, Inkrot S, Tahirovic E, Töpper A, Mehrhof F, Prettin C, Putnikovic B, Neskovic AN, Krotin M, Sakac D, Lainscak M, Edelmann F, Wachter R, Rau T, Eschenhagen T, Doehner W, Anker SD, Waagstein F, Herrmann-Lingen C, Gelbrich G, Dietz R; CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBISELD trial. Eur J Heart Fail. 2011;13(6):670–680. doi: 10.1093/eurjhf/hfr020.
  20. Cullington D, Goode KM, Clark AL, Cleland JG. Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? Eur J Heart Fail. 2012;14(7): 737–747. doi: 10.1093/eurjhf/hfs060.
  21. Арутюнов АГ, Драгунов ДО, Арутюнов ГП, Соколова АВ. Влияние величины дозы основных препаратов на риск повторной госпитализации пациентов с хронической сердечной недостаточностью. Терапевтический архив. 2016;88(1):29–34. doi: 10.17116/ terarkh201688129-34.
  22. Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS; QUALIFY Investigators. Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017;19(11):1414–1423. doi: 10.1002/ejhf.887.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Chernyavskaya T.K., Glezer M.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies